Single psilocybin trip delivers two years of depression relief for cancer patients (phase 2 trial)

Psilocybin plus psychological support showed long-term symptom relief for people with cancer and major depressive disorder in a phase 2 trial. Patients received a single 25 mg psilocybin dose along with therapist support before, during, and after dosing. At about 2 years in follow-up interviews, 53.6% of participants showed a significant reduction in depression, and 50% showed sustained depression reduction including remission. Anxiety also improved at the 2-year mark for 42.9% of participants. The report highlights an ongoing randomized, double-blind trial testing up to two 25 mg doses versus placebo to determine whether additional dosing increases remission rates and duration of benefit.